Pierre Fabre Laboratoire has acquired a stake in MiYé, the French brand of skincare products and dietary supplements dedicated to women's hormonal balance and well-being.
WHO: Co-founded by Caroline de Blignières and Anna Oualid in 2020, MiYé—"good friend" in Provençal—is a brand created by women for women, to help them live better with their hormonal fluctuations and improve their quality of life, from puberty to menopause. With the support of a scientific committee specialized in the endocrine system, MiYé has opted to focus on the hormonal well-being market, targeting the root causes of the often taboo and misunderstood symptoms of hormonal imbalance. The brand consists of 13 products (5 dietary supplements and 8 dermocosmetics).
Pierre Fabre Laboratoire is the second-largest dermocosmetics laboratory in the world, the second-largest private French pharmaceutical group, and the market leader in France for products sold over the counter in pharmacies. Its portfolio includes several medical franchises and international brands, including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Naturactive, Ladrôme, and Pierre Fabre Oral Care. Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan. In 2022, Pierre Fabre Laboratories recorded turnover of €2.7 billion, 69% of which was generated internationally in 120 countries, and invested more than €170 million in R&D.
Pierre Fabre Invest is the venture arm of Pierre Fabre Laboratories that operates under the strategy of acquiring stakes in fast-growing start-ups whose positioning complements their established dermocosmetics brands.
WHY: Since its inception in 1962, Pierre Fabre Laboratoire has been active in women's health via a comprehensive portfolio of medicinal and dermocosmetics products. This strategic alliance with Pierre Fabre Laboratories will enable MiYé to ramp up its R&D investments, carry out clinical studies, bolster its flagship products' scientific and medical endorsement, and continue its development in the pharmacy and drugstore markets. In the short term, MiYé is preparing to develop an awareness-raising and personalized support program via online consultations with naturopaths and micronutritionists.
IN THEIR OWN WORDS: Caroline de Blignières, co-founder of MiYé, shared, "Pierre Fabre Laboratoire's acquisition of a stake in MiYé two years after our launch is a fantastic endorsement. It's an invaluable opportunity to strengthen our R&D resources so that we can promote the democratization of women's hormonal health and work together to redefine the rules of a new ecology for the female body—one that is holistic, transgenerational and, above all, safer."
Anna Oualid, co-founder of MiYé, said, "When we launched MiYé, we set ourselves the ambitious goal of making a medical topic easier to understand for the general public by using cosmetics concepts in tune with women's daily routines, via premium, multi-channel distribution. Who better to support us today than Pierre Fabre, with its long-standing commitment to women's health?"
Frédéric Ennabli, CEO of Pierre Fabre Dermo-Cosmétique, added, "Hormonal balance is a major stake that dermo-cosmetics shall address. With MiYé, Caroline de Blignières and Anna Oualid have found a way to support women from puberty to menopause. They have created a brand with a strong territory, with specialized and differentiating products that are now esteemed by consumers, such as the Happy Cycles Serum. By partnering with MiYé, we are committed to providing our medical and dermatological expertise to develop the best possible responses to take care of all skins affected by hormonal variations. We are thus continuing Pierre Fabre Laboratories’ long-standing commitment to supporting women’s health by enabling pharmacists to accompany them in the best possible way, whether through our dermo-cosmetics or our medicines, which have pioneered the treatment of iron deficiency anemia, a very common condition during pregnancy, and now thanks to this strategic partnership."
2 Article(s) Remaining